PBHMEDIUM SIGNALFINANCIAL10-K

PBH delivered strong revenue growth while maintaining stable profitability despite reduced interest expense and lower cash positions.

The company demonstrates healthy operational expansion with revenue growing substantially, driven by increased market share in key brands rising from 58.6% to 61.5% of revenues. However, the decline in net income alongside revenue growth suggests margin pressure or increased investment spending that investors should monitor closely.

Comparing 2025-05-09 vs 2024-05-15View on EDGAR →
FINANCIAL ANALYSIS

PBH showed robust top-line performance with revenue growing substantially to $975.8M, while net income declined modestly to $190.3M, indicating some margin compression. The company reduced interest expense significantly from $5.2M to $1.8M, likely reflecting debt paydown, though cash positions decreased from $97.9M to $63.9M. Capital expenditures increased to $11.2M, suggesting continued investment in growth initiatives, while current liabilities rose moderately to $120.9M.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-65.4%
$5.2M$1.8M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+36.8%
$713.5M$975.8M

Strong top-line growth of 36.8% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+35.9%
$8.2M$11.2M

Capital expenditure jumped 35.9% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
-34.8%
$97.9M$63.9M

Cash declined 34.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+13.4%
$106.6M$120.9M

Current liabilities rose 13.4% — increased short-term obligations, watch current ratio.

Net Income
P&L
-11.3%
$214.6M$190.3M

Net income declined 11.3% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2025-05-09
PRIOR — 2024-05-15
ADDED
As of May 1, 2025, the registrant had 49,414,707 shares of common stock outstanding.
Our business, business model, competitive strengths and growth strategy face various risks that are described in Part I, Item 1A.
2 The following summarizes the percent of our net revenues by segment during each of the past three fiscal years: March 31, 2025 2024 2023 Segment: North American OTC Healthcare 84.4 % 85.2 % 86.3 % International OTC Healthcare 15.6 14.8 13.7 Total 100.0 % 100.0 % 100.0 % For additional information concerning our business segments, please refer to Part II, Item 7.
Management s Discussion and Analysis of Financial Condition and Results of Operations and Note 18 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
These brands accounted for approximately 83.0%, 83.3% and 81.9% of our total revenues for 2025, 2024, and 2023, respectively.
+7 more — sign up free →
REMOVED
As of May 10, 2024, the registrant had 49,915,366 shares of common stock outstanding.
For more information, see Risk Factors contained in Part I, Item 1A of this Annual Report on Form 10-K.
Our business, business model, competitive strengths and growth strategy face various risks that are described in "Risk Factors" in Part I, Item 1A of this Annual Report on Form 10-K.
2 The following summarizes the percent of our net revenues by segment during each of the past three fiscal years: March 31, 2024 2023 2022 Segment: North American OTC Healthcare 85.2 % 86.3 % 89.1 % International OTC Healthcare 14.8 13.7 10.9 Total 100.0 % 100.0 % 100.0 % For additional information concerning our business segments, please refer to Part II, Item 7, Management s Discussion and Analysis of Financial Condition and Results of Operations and Note 20 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
These brands accounted for approximately 83.3%, 81.9%, and 81.4% of our total revenues for 2024, 2023, and 2022, respectively.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →